Last reviewed · How we verify
SPG302
At a glance
| Generic name | SPG302 |
|---|---|
| Sponsor | Spinogenix |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Intermediate-size Patient Population Expanded Access Protocol
- Efficacy and Safety of Tazbentetol in ALS Participants (PHASE2, PHASE3)
- Study of SPG302 in Adults With Schizophrenia (PHASE2)
- Extension Study of Participants From SPG302-ALZ-101 (PHASE2)
- Extension Study of Participants From SPG302-ALS-001 (PHASE2)
- Study of SPG302 in Adult Participants With Mild-to-Moderate Alzheimer's Disease (AD) (PHASE2)
- Study of SPG302 in Healthy Volunteers and ALS Participants (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SPG302 CI brief — competitive landscape report
- SPG302 updates RSS · CI watch RSS
- Spinogenix portfolio CI